[Skip to Content]
[Skip to Content Landing]
Views 759
Citations 0
News From the Food and Drug Administration
May 16, 2017

Tardive Dyskinesia Drug Approved

JAMA. 2017;317(19):1942. doi:10.1001/jama.2017.5537

The first drug for adults with tardive dyskinesia (TD) has received FDA approval.

Tardive dyskinesia is a neurological disorder that causes repetitive, involuntary movements such as abnormal tongue and lip movements, cheek bulging, foot tapping, shoulder shrugging, and rocking and swaying movements. The condition often results from long-term use of antipsychotic drugs for schizophrenia, bipolar disorder, or other mental health conditions. Drugs such as metoclopromide taken for gastrointestinal disorders also can cause TD.